

**Hands off public quality standards for biologics.**

**They protect patients' health.**

**Support competition which lowers prices.**

**Build trust.**

**So, hands off public standards for biologic medicines.**

A controversial provision tucked inside Senate HELP's draft "Lower Health Care Costs Act" threatens patient safety by removing the requirement that biologic medicines meet public quality standards.

Meeting these public quality standards would be optional for biologic medicines.

The public quality standards set by the U.S. Pharmacopeia (USP) are one reason why Americans have access to the safest medicines in the world.

Public quality standards provide transparency on a quality biologic and enable accountability when adherence to them is required. This provision would destroy this at exactly the time when we need more transparency and accountability, not less.

USP public standards help manufacturers bring biologic medicines to market, fostering competition, which helps lower prices. Inhibiting competition keeps prices high – the exact opposite of what this bill seeks to accomplish.

This provision is all risk with no benefit.

